ART: antiretroviral treatment; CM: cryptococcal meningitis; LTFU: lost to follow-up.
an=22 (after exclusion of cases with confirmed or presumed prevalent CM)
|
| Figure 2: Flowchart representing the number of individuals screened for serum
cryptococcal antigen (sCrAg) prior to ART initiation and six month patient
outcomes. ART: antiretroviral treatment; CM: cryptococcal meningitis; LTFU: lost to follow-up. an=22 (after exclusion of cases with confirmed or presumed prevalent CM) |
